Christian Klein, PhDCXO in Residence & Drug Hunter at Curie.BioSpeaker
Profile
Dr. Christian Klein is currently CXO in Residence & Drug Hunter at Curie.Bio. Previously, he was Distinguished Scientist and Department Head Cancer Immunotherapy Discovery at the Roche Innovation Center Zurich, specialized in the discovery, validation and preclinical development of antibody-based cancer immunotherapies and bispecific antibodies. During his 16+ years at Roche he made major contributions to the development and approval of obinutuzumab, the preclinical development of currently nine clinical stage bispecific antibodies/antibody fusion proteins, and the development of Roche’s proprietary bispecific antibody platforms e.g. the CrossMAb technology and immunocytokine and T-cell bispecific antibody platforms. In 2017 he completed his habilitation in biochemistry at the Ludwig-Maximilians University Munich and acts as external lecturer there.